Last updated on September 2017

A Phase II Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma


Brief description of study

This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID administered orally in continuous 28 day cycles. Screening of subjects to determine eligibility for the study will be performed within 21 days of the first planned dose of tazemetostat. Eligible subjects will be enrolled into one of fivecohorts based on tumor type: - Cohort 1: MRT, RTK, ATRT, or selected tumors with rhabdoid features, including small cell carcinoma of the ovary hypercalcemic type [SCCOHT], also known as malignant rhaboid tumor of the ovary [MRTO] - Cohort 2: Relapsed or refractory synovial sarcoma with SS18-SSX rearrangement - Cohort 3: Other INI1 negative tumors or any solid tumor with an EZH2 gain of function (GOF) mutation, including: epithelioid malignant peripheral nerve sheath tumor (EMPNST), extraskeletal myxoid chondrosarcoma (EMC), myoepithelial carcinoma, other INI1-negative malignant tumors with Sponsor approval (e.g., dedifferentiated chordoma) any solid tumor with an EZH2 GOF mutation including but not limited to Ewing's sarcoma and melanoma - Cohort 4: Renal medullary carcinoma (RMC) - Cohort 5: Epithelioid sarcoma (ES) - Cohort 6: Epithelioid sarcoma (ES) undergoing mandatory tumor biopsy - Cohort 7: Poorly differentiated chordoma (or other chordoma with Sponsor approval) Treatment with tazemetostat will continue until disease progression, unacceptable toxicity or withdrawal of consent, or termination of the study. Response assessment will be evaluated after 8 weeks of treatment and then every 8 weeks thereafter while on study.

Clinical Study Identifier: NCT02601950

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Thierry Jahan, MD

University of California San Francisco
San Francisco, CA United States
  Connect »

Victor Villalobos, MD

University of Colorado Denver
Aurora, CO United States
  Connect »

Steven Attia, MD

Mayo Clinic - Jacksonville
Jacksonville, FL United States
  Connect »

Mark Agulnik, MD

Northwestern Memorial Hospital
Chicago, IL United States
  Connect »

Greg Cote, MD

Massachusetts General Hospital - Cancer Center
Boston, MA United States
  Connect »

George Demetri, MD

Dana Farber Cancer Institute
Boston, MA United States
  Connect »

Rashmi Chugh, MD

University of Michigan
Ann Arbor, MI United States
  Connect »

B Van Tine, MD

Washington University
Saint Louis, MO United States
  Connect »

Mrinal Gounder, MD

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »

Joseph Pressey, MD

Cincinnati Children's Hospital Medical Center
Cincinnati, OH United States
  Connect »

Lara Davis, MD

Oregon Health Sciences University
Portland, OR United States
  Connect »

Nizar Tannir, MD

MD Anderson Cancer Center
Houston, TX United States
  Connect »

Navin Pinto, MD

Seattle Children's Hospital
Seattle, WA United States
  Connect »

Elizabeth Loggers, MD

Fred Hutchinson Cancer Research Center
Seattle, WA United States
  Connect »

David Thomas, MD

Chris O'Brien Lifehouse
Camperdown, Australia
  Connect »

Warren Joubert, MD

Metro South Hospital and Health Service via Princess Alexandra Hospital
Woolloongabba, Australia
  Connect »

Thierry Gil, MD

Institut Jules Bordet Medical Oncology Clinic
Brussels, Belgium
  Connect »

Patrick Schoffski, MD

University Hospital Leuven
Leuven, Belgium
  Connect »

Quincy Chu, MD

Alberta Health Services
Edmonton, AB Canada
  Connect »

Abha Gupta, MD

Princess Margaret Hospital
Toronto, ON Canada
  Connect »

Thierry Alcindor, MD

McGill University Health Centre - Royal Victoria Hospital
Montreal, QC Canada
  Connect »

Antoine Italiano, MD

Institut Bergonie
Bordeaux, France
  Connect »

Jean-Yves Blay, MD

Centre Leon Berard
Lyon, France
  Connect »

Gabriel Malouf, MD

Hospital Pitie Salpetriere
Paris Cedex 13, France
  Connect »

Valerie Laurence, MD

Institut Curie
Paris, France
  Connect »

Olivier Mir, MD

Institut Gustave Roussy
Villejuif, France
  Connect »

Bjoern Hackanson, MD

Children's Hospital Augsburg Klinikum
Augsburg, Germany
  Connect »

Peter Reichardt, MD

Sarcoma Center HELIOS Klinikum Berlin
Berlin, Germany
  Connect »

Silvia Stacchiotti, MD

Instituto Nazionale Tumori - National Cancer Institute Via Giacomo Venezian
Milano, Italy
  Connect »

Wei-Wu Chen, MD

National Taiwan University Hospital
Taipei City, Taiwan
  Connect »

Palma Dileo, MD

London Sarcoma Service Department of Oncology
London, United Kingdom
  Connect »

Robin Jones, MD

Royal Marsden Foundation Trust
London, United Kingdom
  Connect »